Co-Authors
This is a "connection" page, showing publications co-authored by Slim Fourati and Jean-Michel Pawlotsky.
Connection Strength
5.251
-
Differential anti-S antibody titers in vaccinated residents during an outbreak of SARS-CoV-2 variant B.1.351 (ß) in an elderly nursing home. Clin Infect Dis. 2021 Aug 03.
Score: 0.960
-
Frequent Antiviral Treatment Failures in Patients Infected With Hepatitis C Virus Genotype 4, Subtype 4r. Hepatology. 2019 02; 69(2):513-523.
Score: 0.803
-
Editorial: are additional tests needed to predict sustained virologic response in hepatitis C treated with interferon-free direct-acting antiviral combinations? Authors' reply. Aliment Pharmacol Ther. 2018 03; 47(6):849-850.
Score: 0.757
-
Viral kinetics analysis and virological characterization of treatment failures in patients with chronic hepatitis C treated with sofosbuvir and an NS5A inhibitor. Aliment Pharmacol Ther. 2018 03; 47(5):665-673.
Score: 0.747
-
BNT162b2 Messenger RNA Vaccination Did Not Prevent an Outbreak of Severe Acute Respiratory Syndrome Coronavirus 2 Variant 501Y.V2 in an Elderly Nursing Home but Reduced Transmission and Disease Severity. Clin Infect Dis. 2022 02 11; 74(3):517-520.
Score: 0.249
-
Performance of six rapid diagnostic tests for SARS-CoV-2 antigen detection and implications for practical use. J Clin Virol. 2021 09; 142:104930.
Score: 0.240
-
Novel SARS-CoV-2 Variant Derived from Clade 19B, France. Emerg Infect Dis. 2021 05; 27(5):1540-1543.
Score: 0.236
-
Viral genomic, metagenomic and human transcriptomic characterization and prediction of the clinical forms of COVID-19. PLoS Pathog. 2021 03; 17(3):e1009416.
Score: 0.234
-
SARS-CoV-2 viral loads and serum IgA/IgG immune responses in critically ill COVID-19 patients. Intensive Care Med. 2020 Sep; 46(9):1781-1783.
Score: 0.222
-
Sofosbuvir-Daclatasvir-Simeprevir Plus Ribavirin in Direct-Acting Antiviral-Experienced Patients With Hepatitis C. Clin Infect Dis. 2017 Jun 01; 64(11):1615-1618.
Score: 0.180
-
Evaluation of a new random-access HBV DNA molecular assay: The VERIS HBV assay. J Clin Virol. 2017 07; 92:69-74.
Score: 0.179
-
Neutralization heterogeneity of United Kingdom and South-African SARS-CoV-2 variants in BNT162b2-vaccinated or convalescent COVID-19 healthcare workers. Clin Infect Dis. 2021 May 29.
Score: 0.059
-
Performance of 30 commercial SARS-CoV-2 serology assays in testing symptomatic COVID-19 patients. Eur J Clin Microbiol Infect Dis. 2021 Oct; 40(10):2235-2241.
Score: 0.059
-
Clinical description of the broad range of neurological presentations of COVID-19: A retrospective case series. Rev Neurol (Paris). 2021 Mar; 177(3):275-282.
Score: 0.058
-
Maturation and persistence of the anti-SARS-CoV-2 memory B cell response. Cell. 2021 03 04; 184(5):1201-1213.e14.
Score: 0.058
-
Multicenter Evaluation of the Cepheid Xpert Xpress SARS-CoV-2 Test. J Clin Microbiol. 2020 Jul 23; 58(8).
Score: 0.056
-
Inhibition of SARS-CoV-2 Infection by the Cyclophilin Inhibitor Alisporivir (Debio 025). Antimicrob Agents Chemother. 2020 06 23; 64(7).
Score: 0.056
-
Evolutionary Pathways to Persistence of Highly Fit and Resistant Hepatitis C Virus Protease Inhibitor Escape Variants. Hepatology. 2019 09; 70(3):771-787.
Score: 0.052
-
Characterization of the Anti-Hepatitis C Virus Activity of New Nonpeptidic Small-Molecule Cyclophilin Inhibitors with the Potential for Broad Anti-Flaviviridae Activity. Antimicrob Agents Chemother. 2018 07; 62(7).
Score: 0.048